Sensorion Raises €60m to Advance Gene Therapies for Hearing Loss

Sensorion, a clinical-stage biotechnology company focused on developing novel treatments to restore, treat, and prevent hearing loss, has announced a €60 million capital raise to accelerate the advancement of its genetic medicine pipeline. The financing was completed through a reserved offering to selected institutional and strategic investors, underlining growing confidence in the company’s gene therapy programs targeting significant unmet needs in hearing disorders.

The reserved offering involves the issuance of 214,285,714 new ordinary shares at a subscription price of €0.28 per share. Of the total proceeds, Sanofi invested €20 million, reinforcing its strategic interest in Sensorion’s technology and pipeline. The remaining €40 million was subscribed by a group of existing and new institutional investors, including Redmile Group, Artal (advised by Invus), Sofinnova Partners, Cormorant Asset Management, Coastlands Capital, and Sphera Healthcare. Settlement and delivery of the shares are expected to occur around January 30, 2026, subject to customary closing conditions.

The fresh capital will primarily be used to advance Sensorion’s genetic medicine programs, with a particular focus on SENS-601 (GJB2-GT). This gene therapy candidate targets hearing loss caused by mutations in the GJB2 gene, which represent one of the most common genetic causes of congenital hearing loss worldwide. GJB2 mutations are estimated to account for approximately half of autosomal recessive non-syndromic congenital hearing loss cases and are also implicated in early-onset forms of severe age-related hearing loss in adults.

Funding from the offering will support key near-term milestones for SENS-601, including regulatory submissions such as CTA and IND approvals, as well as the enrollment of the first clinical cohort. If successful, SENS-601 will become Sensorion’s second gene therapy program to enter clinical development, following SENS-501, which began clinical testing in 2024.

Nawal Ouzren, Chief Executive Officer of Sensorion, said the financing represents an important step for both the company and patients living with hearing loss. She highlighted Sanofi’s new strategic investment as a strong endorsement of Sensorion’s scientific approach and long-term vision. Ouzren also expressed gratitude to new investors joining the company and to existing shareholders who reaffirmed their support through the transaction.

With the strengthened balance sheet, Sensorion plans to intensify research and development activities across its pipeline. In addition to progressing SENS-601 into the clinic, the company will continue advancing the clinical development of SENS-501, broadening its efforts to address multiple forms of hearing impairment.

The €60 million raise marks a significant milestone in Sensorion’s corporate growth trajectory and reflects increasing momentum in the field of genetic medicines for sensory disorders, an area that has historically lacked disease-modifying treatment options.